Relapse
104
22
28
30
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
5.8%
6 terminated out of 104 trials
83.3%
-3.2% vs benchmark
6%
6 trials in Phase 3/4
17%
5 of 30 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 30 completed trials
Clinical Trials (104)
To Explore the Influencing Factors and Solutions for Patients With Plaque Psoriasis Undergoing Relapse
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
Salvage Treatment With Glofitamab in R/R B-NHL: a GIMEMA-FIL Study
Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC
Motivational Interviews Post Hospitalisation on Maintaining AbstiNence for 1 Year après le Sevrage en Alcool
Isa-Pom-Dex in Elderly/Frail Subjects With RRMM
Autologous CAR-T Cells Targeting B7-H3 in PDAC
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Comparative 3-dimensional Superimposition Analysis of Dentition in Horizontal and Vertical Grower During the Retention Phase -A Prospective Clinical Trial''
Multi-Omics Inflammatory Phenotype for ABPA Recurrence Risk Prediction
A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy
Quantification of Peripheral Blood iNKTs After Allogeneic Stem Cell Transplantation
Study of the Impact on the Evolution of the Disease in the Medium Term of the Implementation of a System of Extended Follow-up by Telephone Interview of Patients With an Eating Disorder Organized by the Nurses of the Eating Disorder Referral Center
Adapted RPM-08 for Substance Use Disorder in Pakistan
A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies
EUS-guided CTCs + Multi-omics: Predicting Pancreatic Cancer Recurrence and Metastases
Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma
Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML
The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia